Optimal adjuvant endocrine therapy for early breast cancer

Women's Health

Volumn 6, Issue 3, 2010, Pages 383-398

  Stuart Harris, Robin ^a   Davis, Alison ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Adjuvant endocrine therapy; Aromatase inhibitors; Breast cancer mortality; Disease free survival; Estrogen receptor; LHRH agonists; Luteinising hormone releasing hormone agonists; Ovarian ablation; Ovarian function suppression; Overall survival; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; FORMESTANE; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; LEUPRORELIN; METHOTREXATE; PACLITAXEL; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; TRIPTORELIN;

AMENORRHEA; ARTHRALGIA; BRAIN ISCHEMIA; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; DEEP VEIN THROMBOSIS; DRUG MECHANISM; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NIGHT SWEAT; OVARIECTOMY; PHARMACOGENETICS; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; REVIEW; SALPINGOOOPHORECTOMY; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR ABLATION; TUMOR RECURRENCE; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOCRINE SYSTEM; FEMALE; HUMANS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 77952121696     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.25     Document Type: Review

References (70)

1. Beatson GT: On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 148, 104-107 (1896). • Interesting paper, mainly from a historical perspective.
2. Beatson GT: On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 148, 162-165 (1896). • Interesting paper, mainly from a historical perspective.
3. Love RJ, Philips J: Oophorectomy for breast cancer: history revisited. J. Natl Cancer Inst. 94, 1433-1434 (2002). • Interesting history of oophorectomy for early breast cancer.
4. Nunn TW: On Cancer of the Breast. J & A Churchill, London, UK 71 (1882).
5. Schinzinger A: Ueber carcinoma mammae. 18th Congress of the German Society for Surgery. Beilage zum Centralblatt fur Chirurgie 16, 55-56 (1889) (Abstract).
6. Boyd S: On oophorectomy in cancer of the breast. BMJ 2, 1161-1167 (1900).
7. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297 (1941).
8. Huggins C, Bergenstal GM: Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 12, 134-141 (1952).
9. Luft R, Olivecrona H: Experiences with hypophysectomy in man. J. Neurosurg. 10, 301-316 (1953).
10. Jensen EV: Studies on growth phenomenon using tritium-labeled steroids. Proceedings of the 4th International Congress of Biochemistry. Vienna, Austria, 1-6 September (1958).
11. Horwitz KB, McGuire WL: Specific progesterone receptors in human breast cancer. Steroids 25, 497-505 (1975).
12. Jonat W, Kaufmann M, Sauerbrei W et al.: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol. 20, 4628-4635 (2002).
13. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic chemotherapy on mortality in early breast cancer. An overview of 61 randomized trials among 28, 896 women. N. Engl. J. Med. 319, 1681-1692 (1988).
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) : Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005). •• The most recent overview of adjuvant chemotherapy and adjuvant endocrine therapy in the management of early breast cancer by the Oxford Group.
15. Swerdlow AJ, Jones ME; for the British Tamoxifen Second Cancer Study Group: Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J. Natl Cancer Inst. 97, 375-384 (2005).
16. Fisher B, Dignam J, Bryant J, Wolmark N: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684-690 (2001).
17. +) or ER untested cancer - preliminary results. J. Clin. Oncol. 26, 15S (2008) (Abstract 513).
18. Bramwell VH, Pritchard KI, Tu D et al.: A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12). Ann. Oncol. 21 (2), 283-290 (2010).
19. International Breast Cancer Study Group: Tamoxifen after adjuvant chemotherapy for premenopausal pateints with lymph node-positive breast cancer: International Breast Cancer Study Group trial 13-93. J. Clin. Oncol. 24, 1332-1341 (2006).
20. Hutchins LF, Green SJ, Ravdin PM et al.: Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102. J. Clin. Oncol. 23, 8313-8321 (2005).
21. Petrek JA, Naughton MJ, Case LD et al.: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J. Clin. Oncol. 24, 1045-1051 (2006).
22. Aebi S, Gelber S, Castiglione-Gertsch M et al.: Is chemotherapy alone adequate for young women with oestrogen-receptorpositive breast cancer? Lancet 355, 1869-1874 (2000).
23. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14, 1718-1729 (1996).
24. Minton SE, Munster PN: Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9, 466-472 (2002).
25. Martin M, Pienkowski T, Mackey J et al.: Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352, 2302-2313 (2005).
26. Shapiro CL, Recht A: Side effects of adjuvant treatment of breast cancer. N. Engl. J. Med. 344, 1997-2008 (2001).
27. Kauff ND, Domchek SM, Friebel TM et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol. 26, 1331-1337 (2008).
28. Hughes LL, Gray RJ, Solin LJ et al.: Efficacy of radiotherapy for ovarian ablation. Results of a breast intergroup study. Cancer 101, 969-972 (2004).
29. Kaufmann M, Jonat W, Kleeberg U et al.: Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J. Clin. Oncol. 7, 1113-1119 (1989).
30. Early Breast Cancer Trialists' Collaborative Group: Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348, 1189-1196 (1996). •• The 1996 Oxford overview of the utility of ovarian ablation or ovarian suppression in the management of 2102 premenopausal women with early breast cancer.
31. Love RR, Duc NB, Allred DC et al.: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J. Clin. Oncol. 20, 2559-2566 (2002).
32. LHRH-Agonists in Early Breast Cancer Overview Group; Cuzick J, Abroisine L, Davidson N et al.: Use of luteinisinghormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369, 1711-1723 (2007). •• Meta-analysis of ovarian function suppression with luteinizing hormone-releasing hormone agonists in 11, 906 premenopausal women with early breast cancer.
33. ™) versus CMF in premenopausal women with node-positive breast cancer. Eur. J. Cancer 39, 1711-1717 (2003).
34. Thomson CS, Twelves CJ, Mallon EA, Leake RE; for the Scottish Cancer Trials Breast Group and the Scottish Cancer Therapy Network: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast 11, 419-429 (2002).
35. Jakesz R, Hausmaninger H, Kubista E et al.: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 20, 4621-4627 (2002).
36. Schmid P, Untch M, Wallwiener D et al.: Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study With Leuprorelin Acetate). Anticancer Res. 22, 2325-2332 (2002).
37. Boccardo F, Rubagotti A, Amoroso D et al.: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J. Clin. Oncol. 18, 2718-2727 (2000).
38. Ejlertsen B, Mouridsen HT, Jensen MB et al.: Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J. Clin. Oncol. 24, 4956-4962 (2006). • Randomized trial showing similar efficacy for ovarian ablation and chemotherapy with cyclophosphamide, methotrexate and fluorouracil in 762 premenopausal women with early breast cancer.
39. Arriagada R, Le MG, Spielmann M et al.: Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann. Oncol. 16, 389-396 (2005). (Pubitemid 40458314)
40. International Breast Cancer Study Group (IBCSG) : Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J. Natl Cancer Inst. 95, 1833-1846 (2003).
41. Davidson NE, O'Neill AM, Vukov AM et al.: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptorpositive breast cancer: results from INT 0101 (E5188). J. Clin. Oncol. 23, 5973-5982 (2005).
42. Baum M, Hackshaw A, Houghton J et al.: Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur. J. Cancer 42, 895-904 (2006).
43. Dowsett M, Stein RC, Coombes RC: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. 43, 155-159 (1992).
44. Celio L, Martinetti A, Ferrari L et al.: Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. 19, 2261-2268 (1999).
45. Jannuzzo MG, Di Salle E, Spinelli R, Pirotta N, Buchan P, Bello A: Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res. Treat. 113, 491-499 (2009).
46. Forward DP, Cheung KL, Jackson L, Robertson JFR: Clinical and endocrine data for goserelin plus anastrozole as second-line therapy for premenopausal advanced breast cancer. Br. J. Cancer 90, 590-594 (2004).
47. Gnant M, Mlineritsch B, Schippinger W et al.: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009). •• Randomized trial of adjuvant endocrine therapy with or without zoledronic acid in 1802 premenopausal women with early breast cancer. This trial showed that zoledronic acid improved disease-free survival.
48. +) breast cancer: the SOFT, TEXT and Perche Trials. Breast 12 (Suppl. 1), S44 (2003) (Abstract P104).
49. Goetz MP, Rae JM, Suman VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot fashes. J. Clin. Oncol. 23, 9312-9318 (2005).
50. Albain KS, Barlow WE, Ravdin PM et al.: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a Phase 3, open-label, randomised controlled trial. Lancet 374, 2055-2063 (2009).
51. Schroth W, Goetz MP, Hamann U et al.: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009). •• Randomized clinical trial that showed a trend to improved disease-free survival for tamoxifen given sequentially after chemotherapy, as opposed to concurrently with chemotherapy.
52. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group: Effects of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer. Lancet Oncol. 9, 45-53 (2008). •• Randomized trial of anastrozole versus tamoxifen as 'up front' adjuvant endocrine therapy in 6241 postmenopausal women with early breast cancer.
53. The BIG 1-98 Collaborative Group: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N. Engl. J. Med. 361, 766-776 (2009). •• Randomized trial of letrozole versus tamoxifen, tamoxifen followed by letrozole or letrozole followed by tamoxifen in 6182 postmenopausal women with early breast cancer.
54. Rea D, Hasenburg A, Seynaeve C et al.: Five years of exemestane compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, Phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res. 69 (Suppl. 24), abstract 11 (2009).
55. Coombes RC, Kilburn LS, Snowdon CF et al.: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study) : a randomised controlled trial. Lancet 369, 559-570 (2007). •• Randomized trial of tamoxifen versus 2-3 years of tamoxifen followed by 2-3 years of exemestane in 4724 postmenopausal women with early breast cancer.
56. Boccardo F, Rubagotti A, Puntoni M et al.: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. J. Clin. Oncol. 23, 5138-5147 (2005).
57. Jakesz R, Gnant M, Greil R et al.: Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group 8. Cancer Res. 69 (Suppl. 2), abstract 14 (2008).
58. Kaufmann M, Jonat W, Hilfrich J et al.: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J. Clin. Oncol. 25, 2664-2670 (2007).
59. Goss PE, Ingle JN, Martino S et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003). •• Randomized trial of letrozole versus placebo in 5187 postmenopausal women who had already received 5 years of tamoxifen.
60. Jakesz R, Greil R, Gnant M et al.: Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Study Group trial 6a. J. Natl Cancer Inst. 99, 1845-1853 (2007).
61. Mamounas EP, Jeong J-H, Wickerham DL et al.: Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J. Clin. Oncol. 26, 1965-1971 (2008).
62. Dowsett M, Cuzick J, Ingle J et al.: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen versus tamoxifen. J. Clin. Oncol. 28, 509-518 (2010). •• Recent meta-analysis of aromatase inhibitors versus tamoxifen in nearly 19, 000 postmenopausal women with early breast cancer.
63. ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
64. Winer EP, Hudis C, Burstein HJ et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
65. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 7, 633-643 (2006). •• An earlier analysis of the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial (anastrozole versus tamoxifen), which demonstrates differences in the toxicities of the two agents.
66. Markopoulos C, Polychronis A, Zobolas V et al.: The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res. Treat. 93, 61-66 (2005). (Pubitemid 41355992)
67. Dixon JM, Renshaw L, Young O et al.: Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J. Clin. Oncol. 26, 1671-1676 (2008).
68. Rose C, Vtoraya O, Pluzanska A et al.: An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer 39, 2318-2327 (2003).
69. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J. Clin. Oncol. 14, 2738-2746 (1996). •• A paper published in 1996 that provides very interesting data on relapse in early breast cancer.
70. Goldhirsch A, Ingle JN, Gelber RD et al.: Threshold for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319-1329 (2009). •• The latest (2009) St Gallen Consensus on the primary therapy of early breast cancer.